We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRU:LSEPrudential plc Analysis

Data as of 2026-03-10 - not real-time

£1,098.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Prudential’s current price sits just above the short‑term moving average and below the mid‑term average, suggesting limited upside momentum in the near term. The relative strength index hovers around the neutral zone, while the MACD histogram remains in negative territory, pointing to bearish pressure but no decisive trend shift. Volume has been slipping, which adds a cautionary note despite the stock trading near its recent support level. On the fundamentals side, the company delivers solid revenue growth, healthy operating margins and a strong cash conversion that underpins a low payout ratio and a sustainable dividend. Valuation metrics show a price‑to‑earnings multiple well below the industry average and a discounted cash flow estimate that implies a substantial upside potential. The balance sheet is manageable with cash roughly matching debt, and the return on equity is respectable for the sector.
The low beta and moderate volatility suggest the stock is less prone to market swings, while exposure to Asian and African markets introduces geographic diversification. Overall, the blend of undervalued pricing, robust cash flow and a steady dividend makes Prudential an attractive candidate for investors looking for a defensive yet growth‑oriented position.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Negative MACD histogram indicating short‑term pressure
  • Price near support with limited volume
  • Sustainable dividend supporting income focus

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and operating margins
  • Undervalued relative to peers and DCF upside
  • Low payout ratio enabling dividend growth

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified exposure to emerging markets
  • Consistent cash flow generation and ROE
  • Defensive beta and steady dividend yield

Key Metrics & Analysis

Financial Health

Revenue Growth20.40%
Profit Margin25.85%
P/E Ratio11.3
ROE19.59%
ROA1.70%
Debt/Equity30.81
P/B Ratio210.3
Op. Cash Flow£2.2B
Free Cash Flow£2.4B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI45.7
Support£1,025.00
Resistance£1,187.50
MA 20£1,106.03
MA 50£1,149.33
MA 200£1,035.52
MACDBearish
VolumeDecreasing
Fear & Greed Index79.93

Valuation

Fair Value£3,038.12
Target Price£1,364.85
Upside/Downside24.30%
GradeUndervalued
TypeBlend
Dividend Yield1.69%

Risk Assessment

Beta0.45
Volatility33.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.